Pancreatic Ductal Adenocarcinoma: Winds of Change
DOI:
https://doi.org/10.52787/agl.v52i1.163Keywords:
Pancreatic ductal adenocarcinoma, pancreatic cancerAbstract
Pancreatic ductal adenocarcinoma is considered one of the neoplasms with the worst prognosis, since approximately 85% of patients have advanced disease at the time of diagnosis. It represents the fourth leading cause of death from cancer, and it is estimated that by the year 2030 it will be the second leading cause.
This situation requires the medical community to be trained to detect and treat patients with pancreatic cancer in a comprehensive manner, which has led to the development of the consensus recommendations recently published by the Pancreas Club of Argentina.1
References
- 1. Pasqua A, Moro M, Alle L, Basso S, Canicoba M, Capitanich P, et al. Recomendaciones para el diagnóstico y tratamiento del adenocarcinoma ductal de páncreas. Acta Gastroenterol Latinoam [Internet].2020;50(s2). https://doi.org/10.52787/XAQM8690
- 2. Goggins M, Alexander Overbeek K, Brand R, Syngal S, Del Chiaro M, Bartsch D, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020 Jan; 69(1):7-17.
- 3. Merlo IG, Fratantoni E, de Santibañes M, Ardiles V, Sanchez Clariá R, Pekolj J, et al. Supervivencia a largo plazo luego de pancreatectomía por cáncer de páncreas. Medicina (B Aires). 2021;81(5):800-807.
- 4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12; 364(19):1817-25.
- 5. Vujasinovic M, Valente R, Del Chiaro M, Permert J, Löhr JM. Pancreatic Exocrine Insufficiency in Pancreatic Cancer. Nutrients 2017, Feb 23; 9(3):183.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Analia V Pasqua, Oscar M Mazza
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
